|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Forner A, Vilana R, Ayuso C, Bianchi L,
Solé M, Ayuso JR, Boix L, Sala M, Varela M, Llovet JM, et al:
Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis:
Prospective validation of the noninvasive diagnostic criteria for
hepatocellular carcinoma. Hepatology. 47:97–104. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bolondi L, Sofia S, Siringo S, Gaiani S,
Casali A, Zironi G, Piscaglia F, Gramantieri L, Zanetti M and
Sherman M: Surveillance programme of cirrhotic patients for early
diagnosis and treatment of hepatocellular carcinoma: A cost
effectiveness analysis. Gut. 48:251–259. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
van Meer S, de Man RA, Siersema PD and van
Erpecum KJ: Surveillance for hepatocellular carcinoma in chronic
liver disease: Evidence and controversies. World J Gastroenterol.
19:6744–6756. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Llovet JM, Burroughs A and Bruix J:
Hepatocellular carcinoma. Lancet. 362:1907–1917. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tateishi R, Shiina S, Teratani T, Obi S,
Sato S, Koike Y, Fujishima T, Yoshida H, Kawabe T and Omata M:
Percutaneous radiofrequency ablation for hepatocellular
carcinoma-An analysis of 1000 cases. Cancer. 103:1201–1209. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Llovet JM and Bruix J: Systematic review
of randomized trials for unresectable hepatocellular carcinoma:
Chemoembolization improves survival. Hepatology. 37:429–442. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Abou-Alfa GK, Schwartz L, Ricci S, Amadori
D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz
B, et al: Phase II study of sorafenib in patients with advanced
hepatocellular carcinoma. J Clin Oncol. 24:4293–4300. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Takayasu K, Arii S, Ikai I, Omata M, Okita
K, Ichida T, Matsuyama Y, Nakanuma Y, Kojiro M, Makuuchi M, et al:
Prospective cohort study of transarterial chemoembolization for
unresectable hepatocellular carcinoma in 8510 patients.
Gastroenterology. 131:461–469. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Llovet JM and Bruix J: Novel advancements
in the management of hepatocellular carcinoma in 2008. J Hepatol.
48(Suppl 1): S20–S37. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Morise Z, Kawabe N, Tomishige H, Nagata H,
Kawase J, Arakawa S, Yoshida R and Isetani M: Recent advances in
the surgical treatment of hepatocellular carcinoma. World J
Gastroenterol. 20:14381–14392. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen X, Liu HP, Li M and Qiao L: Advances
in non-surgical management of primary liver cancer. World J
Gastroenterol. 20:16630–16638. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Forner A, Llovet JM and Bruix J:
Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
El-Serag HB and Rudolph L: Hepatocellular
carcinoma: Epidemiology and molecular carcinogenesis.
Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, Ngai
P, Chu PW, Lam CT, Poon RT and Fan ST: Significance of CD90+ cancer
stem cells in human liver cancer. Cancer Cell. 13:153–166. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ladeiro Y, Couchy G, Balabaud C,
Bioulac-Sage P, Pelletier L, Rebouissou S and Zucman-Rossi J:
MicroRNA profiling in hepatocellular tumors is associated with
clinical features and oncogene/tumor suppressor gene mutations.
Hepatology. 47:1955–1963. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Eguchi S, Takatsuki M, Hidaka M, Soyama A,
Tomonaga T, Muraoka I and Kanematsu T: Predictor for histological
microvascular invasion of hepatocellular carcinoma: A lesson from
229 consecutive cases of curative liver resection. World J Surg.
34:1034–1038. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Roayaie S, Jibara G, Taouli B and Schwartz
M: Resection of hepatocellular carcinoma with macroscopic vascular
invasion. Ann Surg Oncol. 20:3754–3760. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Faber W, Stockmann M, Kruschke JE, Denecke
T, Bahra M and Seehofer D: Implication of microscopic and
macroscopic vascular invasion for liver resection in patients with
hepatocellular carcinoma. Dig Surg. 31:204–209. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sumie S, Nakashima O, Okuda K, Kuromatsu
R, Kawaguchi A, Nakano M, Satani M, Yamada S, Okamura S, Hori M, et
al: The significance of classifying microvascular invasion in
patients with hepatocellular carcinoma. Ann Surg Oncol.
21:1002–1009. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tandon P and Garcia-Tsao G: Prognostic
indicators in hepatocellular carcinoma: A systematic review of 72
studies. Liver Int. 29:502–510. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Poon RT and Fan ST: Hepatectomy for
hepatocellular carcinoma: Patient selection and postoperative
outcome. Liver Transpl. 10(2): Suppl 1. S39–S45. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pandey D, Lee KH, Wai CT, Wagholikar G and
Tan KC: Long term outcome and prognostic factors for large
hepatocellular carcinoma (10 cm or more) after surgical resection.
Ann Surg Oncol. 14:2817–2823. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ishii T, Hatano E, Yasuchika K, Taura K,
Seo S and Uemoto S: High risk of lung metastasis after resection of
hepatocellular carcinoma more than 7 cm in diameter. Surg Today.
44:1900–1905. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Han JH, Kim DG, Na GH, Kim EY, Lee SH,
Hong TH and You YK: Evaluation of prognostic factors on recurrence
after curative resections for hepatocellular carcinoma. World J
Gastroenterol. 20:17132–17140. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jonas S, Bechstein WO, Steinmüller T,
Herrmann M, Radke C, Berg T, Settmacher U and Neuhaus P: Vascular
invasion and histopathologic grading determine outcome after liver
transplantation for hepatocellular carcinoma in cirrhosis.
Hepatology. 33:1080–1086. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Han DH, Choi GH, Kim KS, Choi JS, Park YN,
Kim SU, Park JY, Ahn SH and Han KH: Prognostic significance of the
worst grade in hepatocellular carcinoma with heterogeneous
histologic grades of differentiation. J Gastroenterol Hepatol.
28:1384–1390. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Scaggiante B, Kazemi M, Pozzato G, Dapas
B, Farra R, Grassi M, Zanconati F and Grassi G: Novel
hepatocellular carcinoma molecules with prognostic and therapeutic
potentials. World J Gastroenterol. 20:1268–1288. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Giles RH, van Es JH and Clevers H: Caught
up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta.
1653:1–24. 2003.PubMed/NCBI
|
|
30
|
Tsao CM, Yan MD, Shih YL, Yu PN, Kuo CC,
Lin WC, Li HJ and Lin YW: SOX1 functions as a tumor suppressor by
antagonizing the WNT/β-catenin signaling pathway in hepatocellular
carcinoma. Hepatology. 56:2277–2287. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kim M, Lee HC, Tsedensodnom O, Hartley R,
Lim YS, Yu E, Merle P and Wands JR: Functional interaction between
Wnt3 and Frizzled-7 leads to activation of the Wnt/beta-catenin
signaling pathway in hepatocellular carcinoma cells. J Hepatol.
48:780–791. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wong CM, Fan ST and Ng IO: Beta-Catenin
mutation and overexpression in hepatocellular carcinoma:
Clinicopathologic and prognostic significance. Cancer. 92:136–145.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fujimoto A, Totoki Y, Abe T, Boroevich KA,
Hosoda F, Nguyen HH, Aoki M, Hosono N, Kubo M, Miya F, et al:
Whole-genome sequencing of liver cancers identifies etiological
influences on mutation patterns and recurrent mutations in
chromatin regulators. Nat Genet. 44:760–764. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Guichard C, Amaddeo G, Imbeaud S, Ladeiro
Y, Pelletier L, Maad IB, Calderaro J, Bioulac-Sage P, Letexier M,
Degos F, et al: Integrated analysis of somatic mutations and focal
copy-number changes identifies key genes and pathways in
hepatocellular carcinoma. Nat Genet. 44:694–698. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Guan YS, La Z, Yang L, He Q and Li P: p53
gene in treatment of hepatic carcinoma: Status quo. World J
Gastroenterol. 13:985–992. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Staib F, Hussain SP, Hofseth LJ, Wang XW
and Harris CC: TP53 and liver carcinogenesis. Hum Mutat.
21:201–216. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hussain SP, Schwank J, Staib F, Wang XW
and Harris CC: TP53 mutations and hepatocellular carcinoma:
Insights into the etiology and pathogenesis of liver cancer.
Oncogene. 26:2166–2176. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Vogelstein B, Lane D and Levine AJ:
Surfing the p53 network. Nature. 408:307–310. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bressac B, Kew M, Wands J and Ozturk M:
Selective G to T Mutation Of p53 gene in hepatocellular carcinoma
from southern Africa. Nature. 350:429–431. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang
NJ and Harris CC: Mutational hotspot in the p53 gene in human
hepatocellular carcinomas. Nature. 350:427–428. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Oda T, Tsuda H, Scarpa A, Sakamoto M and
Hirohashi S: p53 gene mutation spectrum in hepatocellular
carcinoma. Cancer Res. 52:6358–6364. 1992.PubMed/NCBI
|
|
42
|
Zhou JD, Shen F, Ji JS, Zheng K, Huang M
and Wu JC: FAM9C plays an anti-apoptotic role through activation of
the PI3K/Akt pathway in human hepatocellular carcinoma. Oncol Rep.
30:1275–1284. 2013.PubMed/NCBI
|
|
43
|
Liu J, Zhang C, Lin M, Zhu W, Liang Y,
Hong X, Zhao Y, Young KH, Hu W and Feng Z: Glutaminase 2 negatively
regulates the PI3K/AKT signaling and shows tumor suppression
activity in human hepatocellular carcinoma. Oncotarget.
5:2635–2647. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Pellegrino R, Calvisi DF, Neumann O,
Kolluru V, Wesely J, Chen X, Wang C, Wuestefeld T, Ladu S, Elgohary
N, et al: EEF1A2 inactivates p53 by way of PI3K/AKT/mTOR-dependent
stabilization of MDM4 in hepatocellular carcinoma. Hepatology.
59:1886–1899. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhou Q, Wong CH, Lau CP, Hui CW, Lui VW,
Chan SL and Yeo W: enhanced antitumor activity with combining
effect of mTOR inhibition and microtubule stabilization in
hepatocellular carcinoma. Int J Hepatol. 2013:1038302013.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Khare S, Zhang Q and Ibdah JA: Epigenetics
of hepatocellular carcinoma: Role of microRNA. World J
Gastroenterol. 19:5439–5445. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Law PT and Wong N: Emerging roles of
microRNA in the intracellular signaling networks of hepatocellular
carcinoma. J Gastroenterol Hepatol. 26:437–449. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zhu Z, Zhang X, Wang G and Zheng H: Role
of MicroRNAs in Hepatocellular Carcinoma. Hepat Mon. 14:e186722014.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Xu L, Beckebaum S, Iacob S, Wu G, Kaiser
GM, Radtke A, Liu C, Kabar I, Schmidt HH, Zhang X, et al:
MicroRNA-101 inhibits human hepatocellular carcinoma progression
through EZH2 downregulation and increased cytostatic drug
sensitivity. J Hepatol. 60:590–598. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Tsai WC, Hsu PW, Lai TC, Chau GY, Lin CW,
Chen CM, Lin CD, Liao YL, Wang JL, Chau YP, et al: MicroRNA-122, a
tumor suppressor microRNA that regulates intrahepatic metastasis of
hepatocellular carcinoma. Hepatology. 49:1571–1582. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Xu T, Zhu Y, Xiong Y, Ge YY, Yun JP and
Zhuang SM: MicroRNA-195 suppresses tumorigenicity and regulates
G1/S transition of human hepatocellular carcinoma cells.
Hepatology. 50:113–121. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Meng F, Henson R, Wehbe-Janek H, Ghoshal
K, Jacob ST and Patel T: MicroRNA-21 regulates expression of the
PTEN tumor suppressor gene in human hepatocellular cancer.
Gastroenterology. 133:647–658. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Gramantieri L, Fornari F, Ferracin M,
Veronese A, Sabbioni S, Calin GA, Grazi GL, Croce CM, Bolondi L and
Negrini M: MicroRNA-221 targets Bmf in hepatocellular carcinoma and
correlates with tumor multifocality. Clin Cancer Res. 15:5073–5081.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Zhang Y, Takahashi S, Tasaka A, Yoshima T,
Ochi H and Chayama K: Involvement of microRNA-224 in cell
proliferation, migration, invasion and anti-apoptosis in
hepatocellular carcinoma. J Gastroenterol Hepatol. 28:565–575.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Tischoff I and Tannapfe A: DNA methylation
in hepatocellular carcinoma. World J Gastroenterol. 14:1741–1748.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Liew CT, Li HM, Lo KW, Leow CK, Chan JY,
Hin LY, Lau WY, Lai PB, Lim BK, Huang J, et al: High frequency of
p16INK4A gene alterations in hepatocellular carcinoma. Oncogene.
18:789–795. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Qin Y, Liu JY, Li B, Sun ZL and Sun ZF:
Association of low p16INK4a and p15INK4b mRNAs expression with
their CpG islands methylation with human hepatocellular
carcinogenesis. World J Gastroenterol. 10:1276–1280.
2004.PubMed/NCBI
|
|
58
|
Mori T, Nomoto S, Koshikawa K, Fujii T,
Sakai M, Nishikawa Y, Inoue S, Takeda S, Kaneko T and Nakao A:
Decreased expression and frequent allelic inactivation of the RUNX3
gene at 1p36 in human hepatocellular carcinoma. Liver Int.
25:380–388. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Park WS, Cho YG, Kim CJ, Song JH, Lee YS,
Kim SY, Nam SW, Lee SH, Yoo NJ and Lee JY: Hypermethylation of the
RUNX3 gene in hepatocellular carcinoma. Exp Mol Med. 37:276–281.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Yoshikawa H, Matsubara K, Qian GS, Jackson
P, Groopman JD, Manning JE, Harris CC and Herman JG: SOCS-1, a
negative regulator of the JAK/STAT pathway, is silenced by
methylation in human hepatocellular carcinoma and shows
growth-suppression activity. Nat Genet. 28:29–35. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Okochi O, Hibi K, Sakai M, Inoue S, Takeda
S, Kaneko T and Nakao A: Methylation-mediated silencing of SOCS-1
gene in hepatocellular carcinoma derived from cirrhosis. Clin
Cancer Res. 9:5295–5298. 2003.PubMed/NCBI
|
|
62
|
Shih YL, Shyu RY, Hsieh CB, Lai HC, Liu
KY, Chu TY and Lin YW: Promoter methylation of the secreted
frizzled-related protein 1 gene SFRP1 is frequent in hepatocellular
carcinoma. Cancer. 107:579–590. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Huang J, Zhang YL, Teng XM, Lin Y, Zheng
DL, Yang PY and Han ZG: Down-regulation of SFRP1 as a putative
tumor suppressor gene can contribute to human hepatocellular
carcinoma. BMC cancer. 7:1262007. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Zhang YJ, Chen Y, Ahsan H, Lunn RM, Lee
PH, Chen CJ and Santella RM: Inactivation of the DNA repair gene
O6-methylguanine-DNA methyltransferase by promoter hypermethylation
and its relationship to aflatoxin B1-DNA adducts and p53 mutation
in hepatocellular carcinoma. Int J Cancer. 103:440–444. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Matsukura S, Soejima H, Nakagawachi T,
Yakushiji H, Ogawa A, Fukuhara M, Miyazaki K, Nakabeppu Y,
Sekiguchi M and Mukai T: CpG methylation of MGMT and hMLH1 promoter
in hepatocellular carcinoma associated with hepatitis viral
infection. Br J Cancer. 88:521–529. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Li Z, Zhang H, Yang J, Hao T and Li S:
Promoter hypermethylation of DNA damage response genes in
hepatocellular carcinoma. Cell Biol Int. 36:427–432. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Schagdarsurengin U, Wilkens L, Steinemann
D, Flemming P, Kreipe HH, Pfeifer GP, Schlegelberger B and Dammann
R: Frequent epigenetic inactivation of the RASSF1A gene in
hepatocellular carcinoma. Oncogene. 22:1866–1871. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Hu L, Chen G, Yu H and Qiu X:
Clinicopathological significance of RASSF1A reduced expression and
hypermethylation in hepatocellular carcinoma. Hepatol Int.
4:423–432. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Xu B, Di J, Wang Z, Han X, Li Z, Luo X and
Zheng Q: Quantitative analysis of RASSF1A promoter methylation in
hepatocellular carcinoma and its prognostic implications. Biochem
Biophys Res Commun. 438:324–328. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Zhong S, Tang MW, Yeo W, Liu C, Lo YM and
Johnson PJ: Silencing of GSTP1 gene by CpG island DNA
hypermethylation in HBV-associated hepatocellular carcinomas. Clin
Cancer Res. 8:1087–1092. 2002.PubMed/NCBI
|
|
71
|
Midorikawa Y, Makuuchi M, Tang W and
Aburatani H: Microarray-based analysis for hepatocellular
carcinoma: From gene expression profiling to new challenges. World
J Gastroenterol. 13:1487–1492. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Okabe H, Satoh S, Kato T, Kitahara O,
Yanagawa R, Yamaoka Y, Tsunoda T, Furukawa Y and Nakamura Y:
Genome-wide analysis of gene expression in human hepatocellular
carcinomas using cDNA microarray: Identification of genes involved
in viral carcinogenesis and tumor progression. Cancer Res.
61:2129–2137. 2001.PubMed/NCBI
|
|
73
|
Shirota Y, Kaneko S, Honda M, Kawai HF and
Kobayashi K: Identification of differentially expressed genes in
hepatocellular carcinoma with cDNA microarrays. Hepatology.
33:832–840. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Nomoto S, Kanda M, Okamura Y, Nishikawa Y,
Qiyong L, Fujii T, Sugimoto H, Takeda S and Nakao A: Epidermal
growth factor-containing fibulin-like extracellular matrix protein
1, EFEMP1, a novel tumor-suppressor gene detected in hepatocellular
carcinoma using double combination array analysis. Ann Surg Oncol.
17:923–932. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Zhang LH and Ji JF: Molecular profiling of
hepatocellular carcinomas by cDNA microarray. World J
Gastroenterol. 11:463–468. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Kanda M, Nomoto S, Okamura Y, Nishikawa Y,
Sugimoto H, Kanazumi N, Takeda S and Nakao A: Detection of
metallothionein 1G as a methylated tumor suppressor gene in human
hepatocellular carcinoma using a novel method of double combination
array analysis. Int J Oncol. 35:477–483. 2009.PubMed/NCBI
|
|
77
|
Okamura Y, Nomoto S, Kanda M, Li Q,
Nishikawa Y, Sugimoto H, Kanazumi N, Takeda S and Nakao A: Leukemia
inhibitory factor receptor (LIFR) is detected as a novel suppressor
gene of hepatocellular carcinoma using double-combination array.
Cancer Lett. 289:170–177. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Kanda M, Nomoto S, Okamura Y, Hayashi M,
Hishida M, Fujii T, Nishikawa Y, Sugimoto H, Takeda S and Nakao A:
Promoter hypermethylation of fibulin 1 gene is associated with
tumor progression in hepatocellular carcinoma. Mol Carcinog.
50:571–579. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Okamura Y, Nomoto S, Kanda M, Hayashi M,
Nishikawa Y, Fujii T, Sugimoto H, Takeda S and Nakao A: Reduced
expression of reelin (RELN) gene is associated with high recurrence
rate of hepatocellular carcinoma. Ann Surg Oncol. 18:572–579. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Hayashi M, Nomoto S, Kanda M, Okamura Y,
Nishikawa Y, Yamada S, Fujii T, Sugimoto H, Takeda S and Kodera Y:
Identification of the A kinase anchor protein 12 (AKAP12) gene as a
candidate tumor suppressor of hepatocellular carcinoma. J Surg
Oncol. 105:381–386. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Wong QW, Lung RW, Law PT, Lai PB, Chan KY,
To KF and Wong N: MicroRNA-223 is commonly repressed in
hepatocellular carcinoma and potentiates expression of Stathmin1.
Gastroenterology. 135:257–269. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Shen J, Wang S, Zhang YJ, Kappil M, Wu HC,
Kibriya MG, Wang Q, Jasmine F, Ahsan H, Lee PH, et al: Genome-wide
DNA methylation profiles in hepatocellular carcinoma. Hepatology.
55:1799–1808. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Okamura Y, Nomoto S, Hayashi M, Hishida M,
Nishikawa Y, Yamada S, Fujii T, Sugimoto H, Takeda S, Kodera Y and
Nakao A: Identification of the bleomycin hydrolase gene as a
methylated tumor suppressor gene in hepatocellular carcinoma using
a novel triple-combination array method. Cancer Lett. 312:150–157.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Hishida M, Nomoto S, Inokawa Y, Hayashi M,
Kanda M, Okamura Y, Nishikawa Y, Tanaka C, Kobayashi D, Yamada S,
et al: Estrogen receptor 1 gene as a tumor suppressor gene in
hepatocellular carcinoma detected by triple-combination array
analysis. Int J Oncol. 43:88–94. 2013.PubMed/NCBI
|
|
85
|
Inokawa Y, Nomoto S, Hishida M, Hayashi M,
Kanda M, Nishikawa Y, Takeda S, Sugimoto H, Fujii T, Yamada S and
Kodera Y: Detection of doublecortin domain-containing 2 (DCDC2), a
new candidate tumor suppressor gene of hepatocellular carcinoma, by
triple combination array analysis. J Exp Clin Cancer Res.
32:652013. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Inokawa Y, Nomoto S, Hishida M, Hayashi M,
Kanda M, Nishikawa Y, Takeda S, Fujiwara M, Koike M, Sugimoto H, et
al: Dynamin 3: A new candidate tumor suppressor gene in
hepatocellular carcinoma detected by triple combination array
analysis. Onco Targets Ther. 6:1417–1424. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Hayashi M, Nomoto S, Hishida M, Inokawa Y,
Kanda M, Okamura Y, Nishikawa Y, Tanaka C, Kobayashi D, Yamada S,
et al: Identification of the collagen type 1 α 1 gene (COL1A1) as a
candidate survival-related factor associated with hepatocellular
carcinoma. BMC Cancer. 14:1082014. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Takano N, Hishida M, Inokawa Y, Hayashi M,
Kanda M, Nishikawa Y, Iwata N, Kobayashi D, Tanaka C, Yamada S, et
al: CCNJ detected by triple combination array analysis as a
tumor-related gene of hepatocellular carcinoma. Int J Oncol.
46:1963–70. 2015.PubMed/NCBI
|
|
89
|
Hishida M, Inokawa Y, Takano N, Nishikawa
Y, Iwata N, Kanda M, Tanaka C, Kobayashi D, Yamada S, Nakayama G,
et al: Protein tyrosine kinase 7: A hepatocellular
carcinoma-related gene detected by triple-combination array. J Surg
Res. 195:444–453. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Revill K, Wang T, Lachenmayer A, Kojima K,
Harrington A, Li J, Hoshida Y, Llovet JM and Powers S: Genome-wide
methylation analysis and epigenetic unmasking identify tumor
suppressor genes in hepatocellular carcinoma. Gastroenterology.
145:1424–1435. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Nishida N, Nishimura T, Nakai T, Chishina
H, Arizumi T, Takita M, Kitai S, Yada N, Hagiwara S, Inoue T, et
al: Genome-wide profiling of DNA methylation and tumor progression
in human hepatocellular carcinoma. Dig Dis. 32:658–663. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Sherman M: Hepatocellular carcinoma:
Epidemiology, surveillance, and diagnosis. Semin Liver Dis.
30:3–16. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Fattovich G, Stroffolini T, Zagni I and
Donato F: Hepatocellular carcinoma in cirrhosis: Incidence and risk
factors. Gastroenterology. 127:5:Suppl 1. S35–S50. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Ladep NG, Lesi OA, Mark P, Lemoine M,
Onyekwere C, Afihene M, Crossey MM and Taylor-Robinson SD: Problem
of hepatocellular carcinoma in West Africa. World J Hepatol.
6:783–792. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Perz JF, Armstrong GL, Farrington LA,
Hutin YJ and Bell BP: The contributions of hepatitis B virus and
hepatitis C virus infections to cirrhosis and primary liver cancer
worldwide. J Hepatol. 45:529–538. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Kao JH and Chen DS: Global control of
hepatitis B virus infection. Lancet Infect Dis. 2:395–403. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Lavanchy D: The global burden of hepatitis
C. Liver Int. 29(Suppl 1): S74–S81. 2009. View Article : Google Scholar
|
|
98
|
El-Serag HB: Hepatocellular carcinoma and
hepatitis C in the United States. Hepatology. 36(5): Suppl 1.
S74–S83. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Donato F, Tagger A, Gelatti U, Parrinello
G, Boffetta P, Albertini A, Decarli A, Trevisi P, Ribero ML,
Martelli C, et al: Alcohol and hepatocellular carcinoma: The effect
of lifetime intake and hepatitis virus infections in men and women.
Am J Epidemiol. 155:323–331. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Baffy G, Brunt EM and Caldwell SH:
Hepatocellular carcinoma in non-alcoholic fatty liver disease: An
emerging menace. J Hepatol. 56:1384–1391. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
White DL, Kanwal F and El-Serag HB:
Association between nonalcoholic fatty liver disease and risk for
hepatocellular cancer, based on systematic review. Clin
Gastroenterol Hepatol. 10:1342–1359. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Poon RT, Fan ST, Lo CM, Liu CL and Wong J:
Long-term survival and pattern of recurrence after resection of
small hepatocellular carcinoma in patients with preserved liver
function: Implications for a strategy of salvage transplantation.
Ann Surg. 235:373–382. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Senthilnathan S, Memon K, Lewandowski RJ,
et al: Extrahepatic metastases occur in a minority of
hepatocellular carcinoma patients treated with locoregional
therapies: Analyzing patterns of progression in 285 patients.
Hepatology. 55:1432–1442. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Zhou XD, Tang ZY, Yang BH, Lin ZY, Ma ZC,
Ye SL, Wu ZQ, Fan J, Qin LX and Zheng BH: Experience of 1000
patients who underwent hepatectomy for small hepatocellular
carcinoma. Cancer. 91:1479–1486. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Shimada M, Hamatsu T, Yamashita Y,
Rikimaru T, Taguchi K, Utsunomiya T, Shirabe K and Sugimachi K:
Characteristics of multicentric hepatocellular carcinomas:
Comparison with intrahepatic metastasis. World J Surg. 25:991–995.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Wang B, Xia CY, Lau WY, Lu XY, Dong H, Yu
WL, Jin GZ, Cong WM and Wu MC: Determination of clonal origin of
recurrent hepatocellular carcinoma for personalized therapy and
outcomes evaluation: A new strategy for hepatic surgery. J Am Coll
Surg. 217:1054–1062. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Nomoto S, Yamashita K, Koshikawa K, Nakao
A and Sidransky D: Mitochondrial D-loop mutations as clonal markers
in multicentric hepatocellular carcinoma and plasma. Clin Cancer
Res. 8:481–487. 2002.PubMed/NCBI
|
|
108
|
Nomoto S, Kinoshita T, Kato K, Otani S,
Kasuya H, Takeda S, Kanazumi N, Sugimoto H and Nakao A:
Hypermethylation of multiple genes as clonal markers in
multicentric hepatocellular carcinoma. Br J Cancer. 97:1260–1265.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Nomoto S, Hishida M, Inokawa Y, Sugimoto H
and Kodera Y: Management of hepatocellular carcinoma should
consider both tumor factors and background liver factors.
Hepatobiliary Surg Nutr. 3:82–85. 2014.PubMed/NCBI
|
|
110
|
Utsunomiya T, Shimada M, Morine Y, Tajima
A and Imoto I: Specific molecular signatures of non-tumor liver
tissue may predict a risk of hepatocarcinogenesis. Cancer Sci.
105:749–754. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Utsunomiya T, Shimada M, Imura S, Morine
Y, Ikemoto T and Mori M: Molecular signatures of noncancerous liver
tissue can predict the risk for late recurrence of hepatocellular
carcinoma. J Gastroenterol. 45:146–152. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Okamoto M, Utsunomiya T, Wakiyama S,
Hashimoto M, Fukuzawa K, Ezaki T, Hanai T, Inoue H and Mori M:
Specific gene-expression profiles of noncancerous liver tissue
predict the risk for multicentric occurrence of hepatocellular
carcinoma in hepatitis C virus-positive patients. Ann Surg Oncol.
13:947–954. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Utsunomiya T, Ishikawa D, Asanoma M,
Yamada S, Iwahashi S, Kanamoto M, Arakawa Y, Ikemoto T, Morine Y,
Imura S, et al: Specific miRNA expression profiles of non-tumor
liver tissue predict a risk for recurrence of hepatocellular
carcinoma. Hepatol Res. 44:631–638. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Hoshida Y, Villanueva A, Kobayashi M, Peix
J, Chiang DY, Camargo A, Gupta S, Moore J, Wrobel MJ, Lerner J, et
al: Gene expression in fixed tissues and outcome in hepatocellular
carcinoma. N Engl J Med. 359:1995–2004. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Nomoto S, Hishida M, Inokawa Y, Takano N,
Kanda M, Nishikawa Y, Fujii T, Koike M, Sugimoto H and Kodera Y:
Expression analysis of THOP1 in background liver, a prognostic
predictive factor in hepatocellular carcinoma, extracted by
multiarray analysis. Ann Surg Oncol. 21(Suppl 3): S443–S450. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Sonohara F, Nomoto S, Inokawa Y, Hishida
M, Takano N, Kanda M, Nishikawa Y, Fujii T, Koike M, Sugimoto H and
Kodera Y: High expression of Janus kinase 2 in background normal
liver tissue of resected hepatocellular carcinoma is associated
with worse prognosis. Oncol Rep. 33:767–773. 2015.PubMed/NCBI
|
|
117
|
Ammerpohl O, Pratschke J, Schafmayer C,
Haake A, Faber W, von Kampen O, Brosch M, Sipos B, von Schönfels W,
Balschun K, et al: Distinct DNA methylation patterns in cirrhotic
liver and hepatocellular carcinoma. Int J Cancer. 130:1319–1328.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Um TH, Kim H, Oh BK, Kim MS, Kim KS, Jung
G and Park YN: Aberrant CpG island hypermethylation in dysplastic
nodules and early HCC of hepatitis B virus-related human multistep
hepatocarcinogenesis. J Hepatol. 54:939–947. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Arai E, Ushijima S, Gotoh M, Ojima H,
Kosuge T, Hosoda F, Shibata T, Kondo T, Yokoi S, Imoto I, et al:
Genome-wide DNA methylation profiles in liver tissue at the
precancerous stage and in hepatocellular carcinoma. Int J Cancer.
125:2854–2862. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Yoshida T, Kato J, Maekita T, Yamashita S,
Enomoto S, Ando T, Niwa T, Deguchi H, Ueda K, Inoue I, et al:
Altered mucosal DNA methylation in parallel with highly active
Helicobacter pylori-related gastritis. Gastric Cancer. 16:488–497.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Lee KH, Hwang D, Kang KY, Lee S, Kim DY,
Joo YE and Lee JH: Frequent promoter methylation of CDH1 in
non-neoplastic mucosa of sporadic diffuse gastric cancer.
Anticancer Res. 33:3765–3774. 2013.PubMed/NCBI
|
|
122
|
Kadara H, Fujimoto J, Yoo SY, Maki Y,
Gower AC, Kabbout M, Garcia MM, Chow CW, Chu Z, Mendoza G, et al:
Transcriptomic architecture of the adjacent airway field
cancerization in non-small cell lung cancer. J Natl Cancer Inst.
106:dju0042014. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J
Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Zheng Z, Liang W, Wang D, Schroder PM, Ju
W, Wu L, Zheng Z, Shang Y, Guo Z and He X: Adjuvant chemotherapy
for patients with primary hepatocellular carcinoma: A
meta-analysis. Int J Cancer. 136:E751–E759. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Kubo S, Takemura S, Sakata C, Urata Y and
Uenishi T: Adjuvant therapy after curative resection for
hepatocellular carcinoma associated with hepatitis virus. Liver
Cancer. 2:40–46. 2013. View Article : Google Scholar : PubMed/NCBI
|
